| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes
|
Loveday, C.
|
|
|
33 |
12 |
p. 1318-1327
|
article
|
| 2 |
An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer
|
Fallon, M.
|
|
|
33 |
12 |
p. 1296-1303
|
article
|
| 3 |
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
|
Selenica, P.
|
|
|
33 |
12 |
p. 1284-1295
|
article
|
| 4 |
At the crossroad between checkpoint blockade and big data analyses: identification of novel biomarkers and potential targets
|
Jurj, A.
|
|
|
33 |
12 |
p. 1214-1216
|
article
|
| 5 |
Editorial Board
|
|
|
|
33 |
12 |
p. iii
|
article
|
| 6 |
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
|
Bareche, Y.
|
|
|
33 |
12 |
p. 1304-1317
|
article
|
| 7 |
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
|
Bayle, A.
|
|
|
33 |
12 |
p. 1328-1331
|
article
|
| 8 |
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Haanen, J.
|
|
|
33 |
12 |
p. 1217-1238
|
article
|
| 9 |
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|
Geyer Jr., C.E.
|
|
|
33 |
12 |
p. 1250-1268
|
article
|
| 10 |
Precision oncology for biliary tract tumors: it’s written in blood!
|
Gouda, M.A.
|
|
|
33 |
12 |
p. 1209-1211
|
article
|
| 11 |
Reply to the Letter to the Editor ‘Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification’ by Hannoun-Levi et al.
|
Franzoi, M.A.
|
|
|
33 |
12 |
p. 1331-1333
|
article
|
| 12 |
Somatic variation in normal tissues: friend or foe of cancer early detection?
|
Acha-Sagredo, A.
|
|
|
33 |
12 |
p. 1239-1249
|
article
|
| 13 |
Table of Contents
|
|
|
|
33 |
12 |
p. i-ii
|
article
|
| 14 |
T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients
|
Pradier, A.
|
|
|
33 |
12 |
p. 1333-1335
|
article
|
| 15 |
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
|
Berchuck, J.E.
|
|
|
33 |
12 |
p. 1269-1283
|
article
|
| 16 |
The end of the second step of the World Health Organization analgesic ladder?
|
Bramati, P.S.
|
|
|
33 |
12 |
p. 1212-1213
|
article
|
Journal description